Michael Cox, MD
Urology · Savannah, GANPI 1245441690
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 62.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $3,354 and has fallen 80.0% since, to $672 in 2025.
Across 121 payments — averaging $64.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Boston Scientific$1K
- AbbVie$454
- Sumitomo Pharma America, Inc.$274
- Astellas Pharma US Inc$253
- Pfizer$158
- plus $698 from 19 others
Across 4 payments — averaging $18,030 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$72K
What the payments were for
- Travel & lodging$1,87624%
- Food & beverage$2,13927%
- Education$3,82349%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $4,914 |
| Boston Scientific | 5 | $1,088 |
| AbbVie(2 entities) | 29 | $454 |
| Sumitomo Pharma America, Inc. | 15 | $274 |
| Astellas Pharma US Inc | 12 | $253 |
| Pfizer | 7 | $158 |
| Merck | 5 | $124 |
| Bayer | 4 | $74 |
| Coloplast | 4 | $66 |
| Endo Pharmaceuticals Inc. | 4 | $64 |
| Amgen | 3 | $50 |
| Laborie Medical Technologies Corp. | 5 | $43 |
| Johnson & Johnson | 3 | $40 |
| Novartis | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| Verity Pharmaceuticals Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Endo USA, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $20 |
| Telix Pharmaceuticals | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Innovation Technologies Inc | 1 | $13 |
| Foundation Medicine, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,859
- AdVance XP$1,026
How this compares
$7,839 in reported general payments places this provider in the 70th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 158 | $93,051 |
| MyrbetriqMirabegron | 88 | $55,096 |
| Tamsulosin Hcl | 555 | $7,434 |
| Silodosin | 54 | $4,704 |
| Finasteride | 427 | $4,211 |
| Trospium Chloride | 45 | $3,506 |
| Methenamine Hippurate | 39 | $2,943 |
| NitrofurantoinNitrofurantoin Macrocrystal | 45 | $1,584 |
| Testosterone | 14 | $1,545 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,501 |
| Solifenacin Succinate | 69 | $1,392 |
| Testosterone Cypionate | 35 | $1,165 |
| Ciprofloxacin Hcl | 117 | $616 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $587 |
| Dutasteride | 14 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $274 | $93,051158 claims |
| Astellas Pharma US IncMyrbetriq | $253 | $55,09688 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 369 urology providers in Georgia.
Other urology in Savannah
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
- Matthew SandAtlanta$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.